| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/09/2006 | US20060029656 Replacement enzyme cochleates |
| 02/09/2006 | US20060029655 Method for preparation of vesicles loaded with biological material and different uses thereof |
| 02/09/2006 | US20060029638 Methods for treating body tissue |
| 02/09/2006 | US20060029635 Growth hormone formulations |
| 02/09/2006 | US20060029611 Prevention and treatment of amyloidogenic disease |
| 02/09/2006 | US20060029609 administering drug biological conjugates used for the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 02/09/2006 | US20060029607 Methods and compositions for modulating tumor growth |
| 02/09/2006 | US20060029606 Insulin-like growth factor (IGF); peptide of given sequence; administered with co-agent such as doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, 5-fluorouracil; anticarcinogen |
| 02/09/2006 | US20060029605 Use of ErbB receptor ligands in treating diabetes |
| 02/09/2006 | US20060029602 secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner |
| 02/09/2006 | US20060029595 Methods of using human receptor protein 4-1BB |
| 02/09/2006 | US20060029593 Immunoglobulins having complementarity determining regions, heavy and light chain variable regions from humans that specifically bind to an antigen with affinity, used for in vivo therapy and diagnosis |
| 02/09/2006 | US20060029592 Methods of treating peripheral arterial occlusions |
| 02/09/2006 | US20060029591 implantable device for providing an osteogenic protein in a biocompatible bioresorbable carrier to defect locus, thereby inducing formation of functional replacement cartilage tissue; medical equipment |
| 02/09/2006 | US20060029590 Administration of neutral endopeptidase to treat inflammatory bowel disease |
| 02/09/2006 | US20060029589 Induction of heterozygous FV Leiden carrier status to reduce mortality in sepsis and to prevent organ damage caused by inflammation and/or ischemia-reperfusion injury |
| 02/09/2006 | US20060029588 Lysyl oxidase-like 1 (LOXL1) and elastogenesis |
| 02/09/2006 | US20060029587 For patients undergoing or who have undergone a surgical a daily nutritional supplement comprising coenzyme Q10; L-cystine; L-glutamine; L-lysine; Vitamin C; Vitamin A; about 100 Vitamin D; Vitamin B1; Vitamin B2; Vitamin B5; Vitamin B6; folic acid; calcium, selenium and zinc |
| 02/09/2006 | US20060029586 Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 02/09/2006 | US20060029585 Methods for reducing morbidity |
| 02/09/2006 | US20060029582 Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy |
| 02/09/2006 | US20060029581 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 02/09/2006 | US20060029580 Method for treating a condition with neural progenitor cells derived from whole bone marrow |
| 02/09/2006 | US20060029579 Contacting a lymphocyte population with an effective amount of a peptide mixture comprising a native agonist peptide from a tumor-associated antigen, wherein the agonist peptide comprises a disclosed amino acid sequence and an analog peptide sequence |
| 02/09/2006 | US20060029578 Composition and method for the repair and regeneration of cartilage and other tissues |
| 02/09/2006 | US20060029573 Pegylated interferon alpha-1b |
| 02/09/2006 | US20060029572 Administering interferon-beta (IFN- beta 9), after failed treatment with interferon- alpha |
| 02/09/2006 | US20060029568 Anionic polymers as toxin binders and antibacterial agents |
| 02/09/2006 | US20060029563 Cutanceous metabolic bio-activator |
| 02/09/2006 | US20060029551 Stable particle formulations of erythropoietin receptor agonists |
| 02/09/2006 | US20060029547 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 02/09/2006 | DE102004036913A1 Verwendung von Pentameren zur Herstellung eines Medikaments Use of pentamers for the preparation of a medicament |
| 02/09/2006 | DE102004031579A1 Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen Peptides to inhibit the interaction of protein kinase A and protein kinase A anchoring proteins |
| 02/09/2006 | CA2784585A1 Glycogen or polysaccharide storage disease treatment method |
| 02/09/2006 | CA2638747A1 Combination drug therapy for reducing scar tissue formation |
| 02/09/2006 | CA2592044A1 Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| 02/09/2006 | CA2579813A1 Method of producing fully carbamylated erythropoietin |
| 02/09/2006 | CA2579214A1 C-terminally truncated interferon |
| 02/09/2006 | CA2575901A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2575866A1 Methods for inducing melanogenesis in a subject |
| 02/09/2006 | CA2575695A1 Vascular tunneler |
| 02/09/2006 | CA2575622A1 Anti-angiogenic peptides and methods of use thereof |
| 02/09/2006 | CA2575610A1 Hpv vaccine comprising peptides from host cell proteins |
| 02/09/2006 | CA2575606A1 Hai-1 and hai-2 in cancer therapy |
| 02/09/2006 | CA2575552A1 Notch mutations leading to increased receptor signaling |
| 02/09/2006 | CA2575513A1 Composition comprising a pulmonary surfactant and a tnf-derived peptide |
| 02/09/2006 | CA2574970A1 A method for managing cholesterol with a serum-free and mitogen-free cytokine mixture |
| 02/09/2006 | CA2574605A1 Cyclic peptides for treatment of cachexia |
| 02/09/2006 | CA2574598A1 Activated protein c inhibits undesirable effects of plasminogen activator in the brain |
| 02/09/2006 | CA2574183A1 Compounds that inhibit hsp90 protein-protein interactions with iap proteins |
| 02/09/2006 | CA2573142A1 Cyclic peptides for treatment of cachexia |
| 02/09/2006 | CA2573110A1 Food ingredients and food products treated with an oxidoreductase and methods for preparing such food ingredients and food products |
| 02/09/2006 | CA2572964A1 Purified amphiphilic peptide compositions and uses thereof |
| 02/09/2006 | CA2570321A1 Inhibitors of iap |
| 02/09/2006 | CA2567795A1 Methods of treating type i diabetes by blocking vegf-mediated activity |
| 02/08/2006 | EP1624068A1 Genetic immunization with cationic lipids |
| 02/08/2006 | EP1624063A2 Chimeric gene encoding the antigenic determinants of four proteins of L. infantum |
| 02/08/2006 | EP1624061A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/08/2006 | EP1624057A2 Process for the obtention of a composition containing hyaluronidase |
| 02/08/2006 | EP1624055A1 Spheroid preparation |
| 02/08/2006 | EP1623994A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/08/2006 | EP1623718A1 Skin collagen production promoter |
| 02/08/2006 | EP1623717A1 Composition against infection with rotavirus and process for producing the same |
| 02/08/2006 | EP1623714A2 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases |
| 02/08/2006 | EP1623230A2 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39) |
| 02/08/2006 | EP1623221A2 Modulators of the p2y10 receptor useful in altering t lymphocyte function |
| 02/08/2006 | EP1623038A2 Process for manufacture of nematode-extracted anticoagulant protein (nap) |
| 02/08/2006 | EP1623036A2 Identification of novel nogo-receptors and methods related thereto |
| 02/08/2006 | EP1623034A2 Mechanisms of myoblast transfer in treating heart failure |
| 02/08/2006 | EP1623012A2 ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 02/08/2006 | EP1622939A1 Active variants of the il-18 binding protein and medical uses thereof |
| 02/08/2006 | EP1622936A1 Method for the production of an n-terminally modified chemotactic factor |
| 02/08/2006 | EP1622935A2 Spex compositions and methods of use |
| 02/08/2006 | EP1622933A2 H. pylori antigens |
| 02/08/2006 | EP1622931A1 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| 02/08/2006 | EP1622929A2 Apo2l (trail) receptor binding peptides and uses thereof |
| 02/08/2006 | EP1622640A1 Glutamate receptor antagonists as neuroprotectives |
| 02/08/2006 | EP1622639A2 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| 02/08/2006 | EP1622638A2 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| 02/08/2006 | EP1622637A2 Method and compositions for nerve regeneration |
| 02/08/2006 | EP1622636A2 Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans |
| 02/08/2006 | EP1622635A2 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
| 02/08/2006 | EP1622634A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/08/2006 | EP1622633A2 Treatment of t-cell mediated diseases |
| 02/08/2006 | EP1622601A1 Pharmaceutical compositions |
| 02/08/2006 | EP1622599A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/08/2006 | EP1622597A2 Modulation of apolipoprotein c-iii expression |
| 02/08/2006 | EP1622596A1 Insoluble globin injectable implant |
| 02/08/2006 | EP1622589A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| 02/08/2006 | EP1622572A2 Conjugates and compositions for cellular delivery |
| 02/08/2006 | EP1622570A2 Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
| 02/08/2006 | EP1622568A2 Interleukin-9 antagonist muteins and their pharmacological methods of use |
| 02/08/2006 | EP1622565A2 Method for inhibiting cellular activation by insulin-like growth factor-1 |
| 02/08/2006 | EP1622563A2 Improved heat shock protein-based vaccines and immunotherapies |
| 02/08/2006 | EP1622448A2 Nasal administration of the lh-rh analog leuprolide |
| 02/08/2006 | EP1599212A4 Combination therapy for the treatment of immunoinflammatory disorders |
| 02/08/2006 | EP1503652A4 Vascularization enhanced graft constructs |
| 02/08/2006 | EP1478393A4 Anti-pathogen treatements |
| 02/08/2006 | EP1352052B1 Method for preparing submicron particle suspensions of pharmaceutical agents |
| 02/08/2006 | EP1297006B1 Regulation of human prostasin-like serine protease |